Protein Engineering vol. 1 no. 6 pp. 499-505, 1987
© 1987 Oxford University Press
OTHER |
Expression in COS cells of a mouse—human chimaeric B72.3 antibody
1Laboratory of Tumor Immunology and Biology, National Cancer Institute NIH, Bethesda, MD 20205, USA Department of Molecular Immunology, Celltech Limited 216-222 Bath Road, Slough SLI 4EN, UK
*To whom reprint requests should be sent
B72.3 is a mouse hybndoma cell-line secreting an IgG1 antibody which recognises an epitope on a tumour-associated antigen, TAG-72. This high molecular weight mucin-like molecule is found on a variety of human neoplasms, including colon, breast and ovarian carcinomas. Chimaeric Immunoglobulin genes with the B72.3 specificity have been constructed by joining the mouse variable regions from cDNA clones to human genomic constant regions using recombinant DNA techniques. The chimaeric heavy and light chain Immunoglobulin genes were placed under the control of a strong viral promoter, and co-transfected into COS-1 cells. SDS–PAGE analysis of the 35S-labelled products demonstrated that the transiently expressed antibodies were correctly synthesised and assembled. The specific binding characteristics of the parent B72.3 antibody were retained by the chimaeric antibody in an antigen-based ELISA. This system gave sufficiently high transient expression of the chlmaerlc antibody molecules to allow rapid physical and Immunological characterisation of the engineered gene products.
Keywords: chimaeric antibody/cancer immunotherapy/DNA transfection/transient expression
Received October 8, 1987;
revised December 8, 1987;
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. J. Lewis, R. J. Pleass, M. R. Batten, J. D. Atkin, and J. M. Woof Structural Requirements for the Interaction of Human IgA with the Human Polymeric Ig Receptor J. Immunol., November 15, 2005; 175(10): 6694 - 6701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Pleass, J. I. Dunlop, C. M. Anderson, and J. M. Woof Identification of Residues in the CH2/CH3 Domain Interface of IgA Essential for Interaction with the Human Fcalpha Receptor (Fcalpha R) CD89 J. Biol. Chem., August 13, 1999; 274(33): 23508 - 23514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.S. Johnston and D.S. Athwal Recombinant anti-polyamine antibodies: identification of a conserved binding site motif Protein Eng. Des. Sel., June 1, 1999; 12(6): 515 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Xiang, L. Prasad, L. T.J. Delbaere, and Z. Jia Light-chain framework region residue Tyr71 of chimeric B72.3 antibody plays an important role in influencing the TAG72 antigen binding Protein Eng. Des. Sel., May 1, 1999; 12(5): 417 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. Mattu, R. J. Pleass, A. C. Willis, M. Kilian, M. R. Wormald, A. C. Lellouch, P. M. Rudd, J. M. Woof, and R. A. Dwek The Glycosylation and Structure of Human Serum IgA1, Fab, and Fc Regions and the Role of N-Glycosylation on Fcalpha Receptor Interactions J. Biol. Chem., January 23, 1998; 273(4): 2260 - 2272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schlom Innovations in Monoclonal Antibody Tumor Targeting: Diagnostic and Therapeutic Implications JAMA, February 3, 1989; 261(5): 744 - 746. [Abstract] [PDF]
|
|
|
|
 |
|
 A.F. Williams, S.J. Davis, Q. He, and A.N. Barclay Structural Diversity in Domains of the Immunoglobulin Superfamily Cold Spring Harb Symp Quant Biol, January 1, 1989; 54(0): 637 - 647. [Abstract] [PDF]
|
|